择期EVAR与开放腹主动脉瘤修复的成本系统评价:成本等效性
该研究比较荷兰四家医院1998-2000年开放修复期与2010-2012年EVAR期择期腹主动脉瘤修复的资源使用和实际成本,采用盈亏平衡法分析。结论认为对于大多数常规修复,EVAR在至少五年随访内不贵于开放修复。
要点
- 开放修复与EVAR再干预率相似(24.2% vs 24.6%,p=.92)。
核心结论
- 对于大多数常规修复,EVAR在至少五年随访内不贵于开放修复。
研究设计与样本
- 比较分析评估1998-2000年 exclusively 开放修复期与2010-2012年EVAR成熟期。
- 收集荷兰四家医院数据估算资源使用,实际成本按基准成本价格和文献综述估算,以2019年价格报告。
- 采用盈亏平衡法定义EVAR与开放修复成本等效时的腔内移植物成本。
主要发现
- 开放修复再干预率为24.2%,EVAR为24.6%,差异无统计学意义(p=.92)。
临床怎么用
- 在评估EVAR与开放修复的经济性时,应考虑设备成本与住院资源使用的平衡。
局限性
- 研究基于荷兰四家医院数据,成本估算可能受地区医疗定价差异影响。
- 采用历史时期比较,可能存在时间相关混杂和指征混杂。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: The suggested high costs of endovascular aneurysm repair (EVAR) hamper the choice of insurance companies and financial regulators for EVAR as the primary option for elective abdominal aortic aneurysm (AAA) repair. However, arguments used in this debate are impeded by time related aspects such as effect modification and the introduction of confounding by indication, and by asymmetric evaluation of outcomes. Therefore, a re-evaluation minimising the impact of these interferences was considered. METHODS: A comparative analysis was performed evaluating a period of exclusive open repair (OR; 1998-2000) and a period of established EVAR (2010-2012). Data from four hospitals in The Netherlands were collected to estimate resource use. Actual costs were estimated by benchmark cost prices and a literature review. Costs are reported at 2019 prices. A break even approach, defining the costs for an endovascular device at which cost equivalence for EVAR and OR is achieved, was applied to cope with the large variation in endovascular device costs. RESULTS: One hundred and eighty-six patients who underwent elective AAA repair between 1998 and 2000 (OR period) and 195 patients between 2010 and 2012 (EVAR period) were compared. Cost equivalence for OR and EVAR was reached at a break even price for an endovascular device of €13 190. The main cost difference reflected the longer duration of hospital stay (ward and Intensive Care Unit) of OR (€11 644). Re-intervention rates were similar for OR (24.2%) and EVAR (24.6%) (p = .92). CONCLUSION: Cost equivalence for EVAR and OR occurs at a device cost of €13 000 for EVAR. Hence, for most routine repairs, EVAR is not costlier than OR until at least the five year follow up.
引用
- Bulder RMA, Eefting D, Vriens PWHE, et al. Editor's Choice - A Systemic Evaluation of the Costs of Elective EVAR and Open Abdominal Aortic Aneurysm Repair Implies Cost Equivalence. Eur J Vasc Endovasc Surg. 2020. PMID: 32800479. doi:10.1016/j.ejvs.2020.07.012
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。